最新ニュース CeriBell (NASDAQ:CBLL) 株価情報

CeriBell

CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

CeriBell Inc

NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) passed Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to become the world's largest publicly traded <a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation">company on Tuesday. </a>
The Details: Nvidia ended Tuesday's trading session with a market capitalization of $3.43 trillion, slightly <a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation">edging out </a>Apple&#8217;s $3.38 trillion valuation, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. The semiconductor giant's dominance in the artificial intelligence chip market has fueled its exponential growth of more than 200% over the past year.&nbsp;
Read More: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Williams Addition Could Be More Important</a>
Nvidia briefly passed Apple <a href="https://www.benzinga.com/news/24/06/39386946/microsoft-apple-step-aside-nvidia-is-now-the-most-valuable-public-company-in-the-world">in market cap </a>in June before sliding over the summer.<a href="https://www.cnbc.com/quotes/MSFT/"> </a>Nvidia&#8217;s ascent to the top highlights the growing importance of AI technology and the pivotal role that Nvidia's specialized hardware plays in its development.&nbsp;
Despite Nvidia's remarkable growth over the past year, analysts remain bullish on the company's growth ahead. The three most recent analyst ratings were released by BofA Securities, Goldman Sachs and Morgan Stanley in October with an average price target of $163.33 between the three. There&#8217;s an implied 17.04% upside for Nvidia stock from these analyst ratings.
Last Friday, S&amp;P Dow Jones announced that Nvidia <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">is joining the Dow Jones Industrial Average on Nov. 8 </a>replacing Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and joining Apple in the blue-chip index. 
NVDA Price Action: According to data from Benzinga Pro, Nvidia shares ended Tuesday's session 2.84% higher at $139.91.&nbsp;
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41690154/shock-october-jobs-report-leaves-fed-in-tight-spot-experts-say-interest-rate-cuts-a">Shock October Jobs Report Leaves Fed In &#8216;Tight Spot:&#8217; Experts Say Interest Rate Cuts Ahead</a></li>
</ul>
Image: Shutterstock

Large Cap

News

Movers

Tech

AAPL

INTC

NVDA

Nvidia Blows Past Apple To Become World's Most Valuable Company

Lake Street analyst Mark Argento maintains Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) with a Buy and raises the price target from $6 to $7.

Price Target

Analyst Ratings

GAIA

Lake Street Maintains Buy on Gaia, Raises Price Target to $7

Lake Street analyst Thomas Flaten maintains Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) with a Buy and raises the price target from $34 to $40.

CSTL

Lake Street Maintains Buy on Castle Biosciences, Raises Price Target to $40

Lake Street analyst Jaeson Schmidt maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $60 to $41.

NSSC

Lake Street Maintains Buy on NAPCO Security Techs, Lowers Price Target to $41

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) .

Guidance

GIFI

Gulf Island Fabrication expect FY2024 adjusted consolidated EBITDA of $11M-$13M.

Lake Street analyst Eric Martinuzzi maintains QuinStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) with a Hold and raises the price target from $20 to $25.

QNST

Lake Street Maintains Hold on QuinStreet, Raises Price Target to $25

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) .

SNDX

Syndax Pharmaceuticals FY2024 R&D expenses forecast: $245M-$250M.

Loop Capital analyst Rob Sanderson maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Buy and raises the price target from $14 to $16.

SNAP

Loop Capital Maintains Buy on Snap, Raises Price Target to $16

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) .

GPOR

Gulfport Energy Full Year 2024: Drilling and completion capex guidance cut to $325M-$335M.

Loop Capital analyst Garik Shmois maintains Knife River Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) with a Buy and lowers the price target from $105 to $100.

Loop Capital Maintains Buy on Knife River Holding, Lowers Price Target to $100

Barclays analyst Blayne Curtis maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight and lowers the price target from $330 to $280.

NXPI

Barclays Maintains Overweight on NXP Semiconductors, Lowers Price Target to $280

It's Election day! Voters are visiting polling locations and social media mavens are sharing opinions and local reports in megathreads, polls and comments on Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>).
Here are some notable threads to follow for election <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631795/reddit-remains-a-favorite-for-wall-street-after-emphatic-beat-and-raise-in-q3">coverage on Reddit.&nbsp;</a>
Polls Open: Subreddit r/politics has over 8.5 million subscribers and features a <a href="https://www.reddit.com/r/politics/comments/1gkefi6/rpolitics_2024_us_elections_live_thread_part_59/">live thread</a> with 59 parts titled, "2024 US Elections Live Thread, Part 59" which contains more than 3,200 comments, voter turnout reports from different locations and live commentary on election developments.&nbsp;
Subreddit r/moderatepolitics has 295,000 members and a <a href="https://www.reddit.com/r/moderatepolitics/">poll titled</a> "Who are you voting for in the 2024 US Presidential Election." At the time of publication, 2,100 Redditors selected Harris, 1,300 selected Trump, 301 selected Other and 842 responded with Not Voting.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/earnings/24/10/41612293/reddit-stock-soars-after-strong-q3-results-q4-guidance-above-estimates-dauqs-grow-17-and-more">Reddit Stock Soars After Strong Q3 Results, Q4 Guidance Above Estimates: DAUq&#8217;s Grow 17% And More</a>
Reddit also features local subreddits like r/Pennsylvania, which has <a href="https://www.reddit.com/r/Pennsylvania/comments/1gjutyd/the_election_day_mega_thread/">a thread</a> titled, "The Election Day Mega Thread" where users can find coverage of the crucial swing state and voting guides and polling locations. The thread also provides local polling updates and news with first-hand accounts from voters across the state.&nbsp;
Where To Find Results: FiveThirtyEight, the data journalism outlet, will feature county-by-county data breakdowns as the polling results come in at its r/fivethirtyeight <a href="https://www.reddit.com/r/fivethirtyeight/">subreddit</a>. It also features discussions about polling accuracy and several live election megathreads.&nbsp;&nbsp;
The r/Journalism <a href="https://www.reddit.com/r/Journalism/">subreddit</a> will provide authoritative sources for results, including updates from the Associated Press and major networks, as well as discussions about result reporting methodology.&nbsp;
Reddit&#8217;s election coverage offers a blend of real-time updates and community engagement across various specialized subreddits, though most users recommend keeping multiple sources open for the most complete picture.&nbsp;
RDDT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Reddit shares ended Tuesday&#8217;s session 12.42% higher at $122.57.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41685913/jpmorgan-to-pay-investors-151-million-after-sec-flags-various-law-violations">JPMorgan To Pay Investors $151 Million After SEC Flags &#8216;Various Law Violations&#8217;</a></li>
</ul>
Photo: Shutterstock

Social Media

Politics

General

RDDT

Redditors Track Election Night: Must-Watch Threads For Trump Vs. Harris Showdown, Other Races

WIIM

WillScot Holdings shares are trading higher following a report suggesting activist investor TOMS has built a stake in the company and is pushing for a review.

JP Morgan analyst Kevin Yin upgrades Yum China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) from Neutral to Overweight and raises the price target from $35.5 to $60.

Upgrades

YUMC

JP Morgan Upgrades Yum China Holdings to Overweight, Raises Price Target to $60

With the first polling places about to close in what is <a href="https://www.benzinga.com/general/politics/24/11/41748843/trump-holds-edge-in-betting-markets-on-election-day-while-experts-call-tight-race-for-harris">expected to be a neck-and-neck election night</a>, reports from Georgia and Michigan say those two swing states are seeing record-high turnout.
What Happened: Turnout in Philadelphia is also reported to be extremely high, with Reuters reporting turnout as much as 50% higher in some precincts than in 2020. A big win in Philadelphia would go a long way toward delivering Pennsylvania &#8211; the largest and tightest swing state &#8211; to Kamala Harris.
At 4:39 p.m. EDT, Donald Trump wrote on Truth Social: &#8220;A lot of talk about massive CHEATING in Philadelphia. Law Enforcement coming!!!&#8221; 
A Philadelphia police spokesman <a href="https://fortune.com/2024/11/05/donald-trump-claims-cheating-police-philadelphia-pennsylvania/">told Fortune</a> they are &#8220;not aware of anything at this time.&#8221; 
Charlie Kirk of pro-Trump group Turning Point Action wrote earlier on X: &#8220;Turnout is mixed and not where we want it to be. We need more people to vote.&#8221;
Also Read: <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">2024 Election Stakes: Potential Sweeps, Split Outcomes In Congressional, Presidential Races</a>
Politico is <a href="https://www.politico.com/live-updates/2024/11/05/2024-elections-live-coverage-updates-analysis/turnout-high-in-georgia-00187458">reporting</a> that turnout in Georgia is on track to surpass 2020, and The Hill <a href="https://thehill.com/homenews/campaign/4973132-michigan-on-pace-to-break-voter-turnout-records-official-says/">says</a> that Michigan may break turnout records.
Why It Matters: High turnout in Philadelphia would be good news for Harris, but even a loss in Pennsylvania would not be fatal to Trump if he performs well in other swing states.
Georgia, Michigan and Pennsylvania were all key to Joe Biden&#8216;s victory in 2020.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41728436/trump-vs-harris-2024-election-deadlocked-final-emerson-poll-shows-one-candidate-with-small-edge-">Trump Vs. Harris: 2024 Election Deadlocked, Final Emerson Poll Shows One Candidate With Small Edge Among Independents</a></li>
</ul>
Image: Shutterstock.

High Turnout Reported In Key States, Trump Baselessly Alleges 'Massive CHEATING' In Philadelphia

A new study <a href="https://tandfonline.com/doi/full/10.1080/21507740.2024.2303154">published</a> in AJOB Neuroscience reveals that most Americans are supportive of <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> use, a psychedelic compound derived from "magic mushrooms," in supervised, licensed settings. As PsyPost <a href="https://www.psypost.org/majority-of-americans-support-supervised-use-of-psilocybin-for-mental-health-and-well-being/">reported</a>, this approval, spanning across political lines, underscores public openness to the controlled use of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psilocybin for mental health treatment</a> and general well-being, despite remaining concerns for policy caution.
Psilocybin, a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule 1</a> drug in the U.S., has long been classified as having a high potential for abuse with no accepted medical use. However, <a href="https://www.benzinga.com/markets/cannabis/24/10/41216395/could-psilocybin-be-a-game-changer-for-millions-battling-depression-new-study-says-yes">recent clinical studies</a> suggest it may help alleviate symptoms of conditions such as treatment-resistant depression when administered under professional supervision. Unlike many medications, psilocybin is considered non-addictive, and studies have found it may also <a href="https://www.benzinga.com/markets/cannabis/24/09/41004196/psilocybin-found-to-be-as-effective-as-lexapro-in-treating-depression-researchers-say">enhance overall well-being</a> in healthy individuals.
This research aimed to explore public perceptions of psilocybin amid <a href="https://www.benzinga.com/markets/cannabis/24/08/40447902/psychedelics-and-mental-health-fda-stalls-but-states-forge-ahead">recent legislative progress</a>, such as Oregon&#8217;s law <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">allowing its therapeutic use</a>. Researchers surveyed 805 Americans, aged 18 to 92, providing background on psilocybin's effects, origin and legal status before asking about support for nationwide legalization.
<h3 class="wp-block-heading">Mental Health Treatment Vs. Well-Being Enhancement</h3>
Participants were presented with two scenarios involving supervised psilocybin use: one for mental health treatment and the other for personal well-being. A strong 89% of participants supported psilocybin use for mental health treatment, while 85% approved its use for well-being enhancement. Though medical use garnered slightly more support, both scenarios saw broad endorsement.
The results show bipartisan support for supervised psychedelic therapy, with younger and more liberal adults showing stronger approval. Older adults and conservatives were more cautious, while those valuing empathy and care were more supportive of psilocybin use in therapy
<h3 class="wp-block-heading">Navigating Caution Amid The Psychedelic Renaissance</h3>
The study also sheds light on the importance of tempering enthusiasm with scientific rigor. According to the researchers, the growing interest in psychedelics comes with the risk of overhyping benefits. Given the early stage of the field, both over- and understatements of trial results are not uncommon. As they noted, while psilocybin shows significant medical potential and a strong safety profile, current evidence doesn&#8217;t support rash conclusions beyond its use in the right context.
While the findings suggest broad public support for supervised psychedelic use, the study focused only on licensed environments, excluding unsupervised or recreational use. Future research could explore attitudes toward these higher-risk aspects.
<h3 class="wp-block-heading">Building Trust And Policy For The Future</h3>
The study authors stressed the need for trust-building and caution in shaping future policies. "If the field can overcome scientific inaccuracies, pursue rigorous research, and build trust—then psychedelics such as psilocybin may one day be seen as a mainstream means to treat mental illness and possibly also to promote overall well-being," they concluded.
With public support reaching bipartisan levels, the potential for psilocybin to become part of standard mental health care is closer to reality than ever, signaling a transformative shift in mental health treatment in the U.S.
Cover image made with AI

Cannabis

Psychedelics

Americans Favor Psilocybin For Mental Health Treatment, Study Finds

DA Davidson analyst Brian Holland maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Buy and raises the price target from $183 to $189.

FRPT

DA Davidson Maintains Buy on Freshpet, Raises Price Target to $189

Hut 8 Says Its Self-Mining Produced 100 BTC In October, Up From 85 BTC In September; Vega Site Buildout Advancing On Track For Q2 2025 Energization

DA Davidson analyst Michael Shlisky maintains Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Neutral and lowers the price target from $94 to $90.

DA Davidson Maintains Neutral on Federal Signal, Lowers Price Target to $90

DA Davidson maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $55 to $48.

DA Davidson Maintains Buy on NAPCO Security Techs, Lowers Price Target to $48

CeriBell: An Interesting EEG Play Going Public

CVS Health, Apollo Global Management, And Novo Nordisk Reported Results

Polyrizon and Gelteq made their public debut on Tuesday in a quiet Halloween week for the IPO market. LATEST IPOS AND DIRECT LISTINGS: Polyrizon (P...

Opening Day: Polyrizon, Gelteq debut in quiet IPO week

JPMorgan initiated coverage of Ceribell (CBLL) with an Overweight rating and $32 price target Ceribell has developed a "proprietary, highly portabl...

Ceribell initiated with an Overweight at JPMorgan

Ceribell, Inc. (CBLL) has received a new Buy rating, initiated by J.P. Morgan analyst, Robbie Marcus. Robbie Marcus has given his Buy rating due to...

Ceribell, Inc. Receives 'Buy' Rating for Unique Diagnostic Platform and Strong Growth Potential

William Blair analyst Margaret Kaczor initiated coverage of Ceribell (CBLL) with an Outperform rating. Published first on TheFly – the ultimate sou...

Ceribell initiated with an Outperform at William Blair

Josh Jennings, an analyst from TD Cowen, has initiated a new Buy rating on Ceribell, Inc. (CBLL). Josh Jennings has given his Buy rating due to a c...

Innovative EEG Solutions Propel Ceribell, Inc. to a Buy Rating

TD Cowen initiated coverage of Ceribell (CBLL) with a Buy rating and $31 price target The company's technology tackles the limitations of conventio...

Ceribell initiated with a Buy at TD Cowen

BofA initiated coverage of Ceribell (CBLL) with a Buy rating and $32 price target Published first on TheFly – the ultimate source for real-time, ma...

Comments

CeriBell

ニュース

最新ニュース CeriBell (NASDAQ:CBLL) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル